
Coherence Neuro raised a $45M Series A co-led by Founders Fund and the OpenAI Startup Fund. The company develops brain implants for glioblastoma, starting with CIPHER, a thin-film cortical probe first tested in three patients this summer. The funding will support its first long-term human trial, an FDA Breakthrough Device designation application, and preclinical research in pancreatic cancer.
Coherence Neuro placed its investigational cancer implant in three patients during brain tumor resection surgery at Royal Melbourne Hospital, marking the company's first in-human move. Led by Dr. Andrew Morokoff, who also performed Synchron's first implant, Coherence's trial will evaluate the cortical probe's ability to map and stimulate brain activity intraoperatively with high spatial resolution. Each placement lasted roughly 30 minutes. The data will be used for SOMA-1, Coherence's second-generation implant designed to sense and stimulate the tumor microenvironment as a longer-term therapeutic approach to brain cancer.